Figure 3.

Potential Targets for APS Treatment. Several molecules can interfere with the binding process of aPL to ECs, including αEPCR 1496, miRNAs, peptides targeting domains I and V of β2GPI, methyl-β-cyclodextrin, LRP8 ligand-binding antagonists, monoclonal antibodies, and plasminogen activator-coated nanobubbles. Other molecules act on intracellular signaling pathways, such as Hyperoside, Vitamin D, and mTOR inhibitors like Sirolimus and RapaLink-1. Additionally, some molecules target downstream signal transduction in ECs, including monoclonal antibodies, the TF inhibitor NAPc2, and a combination of pravastatin, low molecular weight heparin, and low dose aspirin.